2 - PDF Free Download

15 4 1 15 1 31 3 15 1 162 272 CPA 46 28 CPA 1 CPA 4

CPA 5

a. ( ) ACLS 15 5 17 b. 1 12 c. 25 29 6

CPA CPA 1 CPA Randomized Controlled Trial, RCT RCT CPA CPA 1 Dr 9

CPA CPA 15 4 1 15 1 31 CPA CPA CPA 3 65 CPR 1 * CPR km 2 85 55 12.6 33 9 65 11.1 33 119 86 13.8 425 148 854 14.9 494 166 248 16. 25 26 284 12. 137 21 332 19.4 662** 23 317 17.2 529** * ** 1

1 Phase 11 Phase Phase CPA CPA CPA 2 2 P <.5 +1 +1 +1 2 11

CPA 15 1 CPA 41 162 79 272 CPA CPA 41 149 47 64 41 282 74 28 41 169 87 81 1 41 224 99 125 41 39 12 27 41 79 38 41 41 44 16 28 41 25 61 111 33 162 272 67.3 69.4 P=.255 (t ) 161.7 6238.3 16962.1 1337.9 P=.933 ( 2 ) 1274.1 4125.3 1.6 22281.6 4416.2 62.2 P=.25 ( 2 ) ( CPA12 49 4.8 CPA41 11 25. CPA222 52 23.4 CPA44 14 31.8 CPA 12

5 3 5 161 272 14.1 6.2 6.3 2.7 11 27 46.4 28.4 13.6 8.7 3 13

CPA 3-6-1 Phase.965* Dr.39 123 (24.1%) (75.9%) 67 24 (24.6%) (75.%) 1 (.4%) 162 272 95CI.6131.52.879 6-2 Phase 1.522* Dr.54 18 (33.3%) (66.7%) 67 24 (24.6%) (75.%) 1 (.4%) 162 272 95CI.9932.335.53 6-3 Phase 1.744* Dr.59 13 (36.4%) (63.6%) 67 24 (24.6%) (75.%) 1 (.4%) 162 272 95CI1.1432.661.1 14

3-7-1 Phase 1 Dr.15 147 (9.3%) (9.7%) 16 254 (5.9%) (93.4%) 1.62* 2 (.7%) 162 272 95CI.7783.372.194 7-2 Phase 1 Dr.17 145 (1.5%) (89.5%) 16 254 (5.9%) (93.4%) 1.861* 2 (.7%) 162 272 95CI.9173.795.84 7-3 Phase 1 Dr.17 145 (1.5%) (89.5%) 16 254 (5.9%) (93.4%) 1.861* 2 (.7%) 162 272 95CI.9173.795.84 15

3- CPA 8-1 Phase 5.53* Dr.39 123 162 95CI2.7179.398 (24.1%) (75.9%) <.1 16 255 1 272 (5.9%) (93.8%) (.4%) 8-2 Phase 7.969* Dr.54 18 162 95CI4.36714.543 (33.3%) (66.7%) <.1 16 255 1 272 (5.9%) (93.8%) (.4%) 8-3 Dr.45 18 (33.3%) (66.7%) 52 23 (2.3%) (79.3%) 1.76* 1 (.4%) 148 256 95CI1.72-2.713.23 16

CPA 4-9-1 Phase 1.233* Dr.33 87 (27.5%) (72.5%) 52 169 (23.4%) (76.1%) 1 (.5%) 12 222 95CI.7422.47.418 9-2 Phase 1.815* Dr.43 77 (35.8%) (64.2%) 52 169 (23.4%) (76.1%) 1 (.5%) 12 222 95CI1.1172.95.16 9-3 Phase 2.243* Dr.49 71 (4.8%) (51.2%) 52 169 (23.4%) (76.1%) 1 (.5%) 12 222 95CI1.393.62.1 17

- 1-1 Phase 1 Dr.12 18 (1.%) (9.%) 1 21 (4.5%) (94.6%) 2.333* 2 (.9%) 12 222 95CI.9775.573.51 1-2 Phase 1 Dr.13 17 (1.8%) (89.2%) 1 21 (4.5%) (94.6%) 2.551* 2 (.9%) 12 222 95CI1.836.9.27 1-3 Phase 1 Dr.13 17 (1.8%) (89.2%) 1 21 (4.5%) (94.6%) 2.551* 2 (.9%) 12 222 95CI1.836.9.27 18

4- CPA 11-1 Phase 6.69* Dr.33 87 12 95CI3.4812.86 (27.5%) (72.5%) <.1 13 28 1 222 (5.9%) (93.7%) (.5%) 11-2 Phase 8.935* Dr.43 77 12 95CI4.55817.517 (35.8%) (64.2%) <.1 13 28 1 222 (5.9%) (93.7%) (.5%) 4- CPA 12 2.17* Dr.36 71 17 95CI1.2923.737 (33.6%) (66.4%).3 39 169 1 29 (18.7%) (8.9%) (.5%) 19

CPA 5-13-1 Phase Dr.11 (26.8%) 3 (73.2%) 14 3 (31.8%) (68.2%).786 41 44 95CI.382.7.614 5-13-2 Phase Dr. 4 (9.8%) 37 (9.2%) 1 43 (2.3%) (97.7%) 4.649 41 44 95CI.49743.45.192 2

6-1 CPA12 14-1 VT/VF PEA Asystole 1 (27.8%) 2 ( 5.3%) 1 ( 2.2%) 6 (16.7%) 9 (23.7%) 5 (1.9%) 4 (11.1%) 3 ( 7.9%) 3 ( 6.5%) (.%) 1 ( 2.6%) 5 (1.9%) 16 (44.4%) 23 (6.5%) 32 (69.9%) 36 (1%) 38 (1%) 46 (1%) 21

6-2. CPA222 14-2 VT/VF PEA Asystole 12 (25.%) (.%) 1 (.9%) 1 (2.8%) 15 (26.8%) 14 (12.1%) 26 (54.2%) 41 (73.2%) 12 (87.9%) 48 (1%) 56 (1%) 116 (1%) 22

1 2 3 4 5 6 7 ( ) 52. 58.3 5. 2. 45.5 18.1 14.3. 114 52. 7-2 114 Phase Phase Total 23

1 7 8 CPA 9 1 CPA AG A B C D E F G DF C E 24

A B C D E F G DF C E 1 25

1. CPA CPA CPA CPA CPA CPA 2. CPA CPA 16 25 4 46 28 5 3 CPA CPA 9-2 9-1 26

CPA 1 1 11-1 11-2 12 CPA CPA CPA 41 44 CPA CPA CPA CPA 27

CPR on line MC CPR on line MC 5 1mg iv on line MC iv 33

CPR On line MC CPR on line MC 5 1mg iv on line MC on line MC 1mg iv 5 iv on line MC iv 5 39